Cytokinetics Logo
US23282W6057
A1W1KK
CYTK

Cytokinetics

Previsión

El precio objetivo medio de los analistas es de 97,64 € (+110,89 %). La mediana es de 102,07 € (+120,45 %).

Comprar
  34
Mantener
  1
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Cytokinetics added to Polaris portfolio after Myqorzo seen superior to Camzyos

    Polaris Capital Management added Cytokinetics to its Q2 2026 Global Equity Strategy, citing FDA approval of Myqorzo for hypertrophic cardiomyopathy and its perceived superiority to Bristol Myers Squibb's Camzyos in symptom relief and dosing simplicity. Cytokinetics closed at $67.59 on Sept. 22, 2026, with a market cap of $9.4 billion, a 52-week range of $47.22–$88.31 and a one-month decline of 14.66% versus a 52-week gain of 39.97%. Polaris noted the company amid strong quarter-wide gains driven by AI holdings, and hedge fund ownership of Cytokinetics rose to 78 portfolios at quarter end. » Más en finance.yahoo.com


  • Cytokinetics bets on MYQORZO expansion in HCM and prepares NHCM approval

    At the Citigroup conference, Cytokinetics reported a better-than-expected launch for MYQORZO in obstructive HCM, capturing a 40% share of new prescriptions by the end of Q2 2026. ACACIA-HCM phase 3 data showed superiority in non-obstructive HCM (NHCM) and support a planned regulatory filing; the company estimates NHCM could represent about 50% of the HCM market. There was a slight imbalance of serious heart-failure events in ACACIA, which the company views as manageable and plans to publish additional safety data. Cytokinetics plans to increase SG&A spending to support NHCM expansion and its European roll‑out (Germany launched, UK Q4 2026, other markets in 2027) and is advancing the COMET-HF confirmatory study of Omecamtiv Mecarbil in parallel. » Más en de.investing.com


  • Cytokinetics beats Q2 2026 estimates thanks to launch of MYQORZO

    Cytokinetics reported a loss of $1.50 per share for Q2 2026 on revenue of $28.6 million, well above the consensus estimate of $17.09 million. The driver was the launch of the heart drug MYQORZO, which generated net product revenues of $25.3 million and treated more than 1,500 patients by the end of the quarter. The company raised its 2026 spending expectations due to increased commercial investments and holds $1.7 billion in cash. Management emphasized continued market momentum but noted risks from high costs, reliance on MYQORZO and reimbursement uncertainties. » Más en de.investing.com


  • MHRA grants Cytokinetics approval for Aficamten in the UK

    The MHRA has approved Cytokinetics’ Aficamten (MYQORZO) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. NICE recommends use in England and Wales for patients in NYHA classes II–III as an add‑on to optimized standard therapy or as monotherapy when there are contraindications. The decision is based on the phase‑3 SEQUOIA‑HCM study, which showed a mean difference in peak oxygen uptake of 1.7 ml/kg/min (p < 0.001) versus placebo. Common adverse events included hypertension, palpitations, dizziness and systolic dysfunction; availability through the NHS is expected later this year. » Más en de.investing.com


  • Cytokinetics gains momentum as Myqorzo commercial rollout expands

    Cytokinetics is transitioning from development to commercial stage following regulatory approvals for Myqorzo in the US, Europe and China, with early physician adoption and patient response supporting initial sales momentum. Positive trial readouts are expanding the drug's potential into related cardiac indications, while a differentiated mechanism and a pipeline of next-generation candidates could broaden its addressable market. Market interest and volume-supported price action indicate accumulation as investors reassess long-term growth and pricing power in a market with limited competition. » Más en finance.yahoo.com

Datos financieros

En el último trimestre, Cytokinetics tuvo unos ingresos de 41,99 M € y un beneficio neto de -167,8 M €

(EUR) septiembre de 2026
YoY
Ingresos 41,99 M 2445,01 %
Beneficio bruto 40,03 M 2326,43 %
Beneficio neto -167,8 M 35,68 %
EBITDA -130,61 M 44,70 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
6515,27 M €
Número de acciones
139,3 M
Máximo/mínimo de 52 semanas
80,48 € - 46,52 €
Dividendos No
Beta
0,36
Ratio P/E
-8,51
Ratio PEG
-8,41
Ratio P/B
-22,22
Ratio P/S
63,10

Perfil de la empresa

Cytokinetics, Incorporated, una empresa biofarmacéutica en fase avanzada de desarrollo, se dedica al descubrimiento, desarrollo y comercialización de activadores e inhibidores musculares como posibles tratamientos para enfermedades debilitantes. La empresa desarrolla candidatos a fármacos de molécula pequeña diseñados principalmente para influir en la función y la contractilidad muscular. Sus candidatos incluyen omecamtiv mecarbil, un novedoso activador de la miosina cardíaca que se encuentra en ensayo clínico de fase III en pacientes con insuficiencia cardíaca; y reldesemtiv, un activador de la troponina del músculo esquelético, que se encuentra en ensayo clínico de fase III para el tratamiento de la esclerosis lateral amiotrófica y la atrofia muscular espinal. La empresa también desarrolla CK-136, un novedoso activador de la troponina cardíaca que se encuentra en ensayo clínico de fase I; aficamten, un novedoso inhibidor de la miosina cardíaca, que se encuentra en ensayo clínico de fase III para el tratamiento de pacientes con miocardiopatía hipertrófica obstructiva sintomática; y CK-3772271, un inhibidor de la miosina cardíaca de molécula pequeña que se encuentra en ensayo clínico de fase I. Cytokinetics, Incorporated mantiene una alianza estratégica con Astellas Pharma Inc. La empresa se constituyó en 1997 y tiene su sede en South San Francisco, California.

Nombre
Cytokinetics
CEO
Robert I. Blum
Sede South San Francisco, ca
Estados Unidos
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
30/04/2004
Empleados 673

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
CYTK
Frankfurt
KK3A.F
Düsseldorf
KK3A.DU
SIX
KK3A.SW
München
KK3A.MU
🍪

Parqet  usa cookies. Más información